- This is a randomized, open label prospective, Phase II study in subjects with non-muscle invasive high grade urothelial carcinoma of the bladder who have failed at least one induction course of intravesical BCG, randomized to one of the following arms: TICE BCG +PANVAC or TICE BCG alone. Randomization is stratified by BCG treatment subgroup.